Article

Rituximab-induced subacute interstitial pneumonitis: a case report and review of literature.

Department of Medical Oncology, M. S. Ramaiah Medical College, Bangalore 560 054, India.
Journal of cancer research and therapeutics (impact factor: 0.83). 6(3):344-6. DOI:10.4103/0973-1482.73356
Source: PubMed

ABSTRACT Rituximab is a chimeric anti-CD20 monoclonal antibody used to treat CD20+ non-Hodgkin's lymphoma (NHL). Some pulmonary adverse reactions such as cough, rhinitis, bronchospasm and dyspnea are relatively common. Severe respiratory conditions like cryptogenic organizing pneumonia, interstitial pneumonitis have rarely been reported. We present a case of interstitial pneumonitis in a patient who was treated with R-CHOP for extranodal NHL. He responded to the steroids.

0 0
 · 
0 Bookmarks
 · 
28 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

bronchospasm
 
CD20+ non-Hodgkin's lymphoma
 
chimeric anti-CD20 monoclonal antibody
 
interstitial pneumonitis
 
pulmonary adverse reactions
 
Severe respiratory conditions
 
steroids
 

Murali Subramanian